Noubar Afeyan - BG Medicine Insider

BGMD -- USA Stock  

USD 0.048  0.008  20.00%


Dr. Noubar B. Afeyan Ph.D. is an Independent Director of BG Medicine Inc. since July 25 2011. He is founder and served as the Board of Directors since inception in 2000. He has served as Managing Partner and Chief Executive Officer of Flagship Ventures an early stage VC firm since he cofounded the firm in 2000. Prior to founding Flagship Ventures in 2000 Dr. Afeyan participated in cofounding and helping launch the following ventures PerSeptive Biosystems ChemGenics Pharmaceuticals EXACT Sciences Agenus Color Kinetics and Celera Genomics. Dr. Afeyan was Chief Executive Officer of PerSeptive Biosystems during its five years as a public company and until its merger with Perkin Elmer Corporationrationration. During the past five years Dr. Afeyan has served on the board of directors of Helicos BioSciences. Additionally he currently serves as a director of the following private companies Affinnova Inc. Aero Designs BIND Therapeutics Inc. Eleven Biotherapeutics Ensemble Therapeutics Joule Unlimited Inc. LS9 Inc. Moderna Therapeutics and Pronutria. He earned his Ph.D. in biochemical engineering from the Massachusetts Institute of Technology following a B.S. in chemical engineering from McGill University. Dr. Afeyan has authored numerous scientific publications and patents and is currently a Senior Lecturer at MIT in the Sloan School of Management
Age: 52  Founder Since 2011      

Noubar Afeyan Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (75.95) % which means that it has lost $75.95 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (902.64) % meaning that it created substantial loss on money invested by shareholders.

Entity Summary

BG Medicine, Inc. engages in development and commercialization of diagnostic products used to guide the patients suffering from heart failure and related disorders in the United States. BG Medicine, Inc. was founded in 2000 and is headquartered in Waltham, Massachusetts. BG Medicine operates under Diagnostics Research classification in USA and traded on OTC Market. It employs 5 people.BG Medicine (BGMD) is traded on OTC Market in USA. It is located in MASSACHUSETTS, U.S.A and employs 5 people. BG Medicine is listed under Pharmaceutical Products category by Fama And French industry classification.

BG Medicine Leadership Team

James Connor, Director
Harry Wilcox, Director
Stelios Papadopoulos, Director, MBA
Aram Adourian, SVP, Ph.D
Stephen Hall, CFO, MBA
Jeffrey Luber, Director, MBA
Paul Sohmer, CEO
Noubar Afeyan, Founder
James OConnor, Director

Stock Performance Indicators